Highlights Revance Therapeutics, Inc.

Equities

RVNC

US7613301099

Market Closed - Nasdaq Other stock markets 01:30:00 11/05/2024 am IST			5-day change	1st Jan Change
3.32 ^USD	-22.61%		-15.95%	-62.23%

10/05	Needham Adjusts Price Target on Revance Therapeutics to $12 From $18, Maintains Buy Rating	MT
10/05	Piper Sandler Cuts Price Target on Revance Therapeutics to $11 From $20, Maintains Overweight Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (RVNC) REVANCE THERAPEUTICS Reports Q1 Revenue $51.9M, vs. Street Est of $56.7M	10/05	MT
Revance Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Revance Therapeutics, Inc. Announces the Commercial Launch of DAXXIFY (Daxibotulinumtoxina-Lanm) for Injection for the Treatment of Cervical Dystonia	10/05	CI
AbbVie raises annual profit forecast on strong Skyrizi sales	26/04	RE
Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting	12/04	CI
Earnings Flash (RVNC) REVANCE THERAPEUTICS Posts Q4 Revenue $69.8M	29/02	MT
Revance Therapeutics, Inc. Provides Revenue Guidance for the Year 2024	29/02	CI
Revance Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	29/02	CI
Revance Therapeutics Gets Permanent J-Code for Daxxify	02/02	DJ
Revance Therapeutics, Inc. Receives Permanent J-Code for DAXXIFY and Announces Publication of Daxify Pivotal Study (ASPEN-1) Results in Neurology	02/02	CI
AbbVie profit beats estimates as Humira, Botox sales weather hit from rivals	02/02	RE
US Consumer Advocacy Group Seeks to Strengthen Warnings on Botox Labeling	12/12	MT
US Consumer group seeks stronger warnings on Botox, similar treatments	12/12	RE
Revance Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
Earnings Flash (RVNC) REVANCE THERAPEUTICS Posts Q3 Revenue $56.8M, vs. Street Est of $58.7M	09/11	MT
Revance's Botox rival gets FDA approval for painful neck muscle condition	14/23/14	RE
U.S. FDA Approves First Therapeutic Indication for Revance's Daxxify (Daxibotulinumtoxina-Lanm) for Injection for the Treatment of Cervical Dystonia	14/23/14	CI
Revance Therapeutics' Q2 Net Loss Narrows, Revenue Increases	09/23/09	MT
Earnings Flash (RVNC) REVANCE THERAPEUTICS Reports Q2 Revenue $58.1M, vs. Street Est of $58.9M	09/23/09	MT
Revance Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/23/09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Revance Therapeutics, Inc.

Equities

RVNC

US7613301099

Highlights

Filters